Avalo Therapeutics

Avalo Therapeutics

Discovers, develops and commercializes neuroscience drugs.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
N/A

€0.0

round
investor investor investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor investor investor investor investor investor investor

€0.0

round
*
N/A

$75.0m

Post IPO Equity
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2018201920202021202220232024
Revenues0000000000000000000000000000
% growth(33 %)(6 %)(59 %)(29 %)260 %(89 %)(77 %)
EBITDA0000000000000000000000000000
% EBITDA margin(56 %)------
Profit0000000000000000000000000000
% profit margin(222 %)(94 %)(914 %)(1680 %)(233 %)(1639 %)(7966 %)
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000

Source: Company filings or news article

More about Avalo Therapeutics
Made with AI
Edit

Cerecor Inc. is a biopharmaceutical company focused on developing innovative therapies for rare pediatric and orphan diseases. The company operates in the healthcare and biotechnology sectors, targeting unmet medical needs with a robust pipeline of forward-thinking ideas. Cerecor serves patients who suffer from rare conditions, often with limited treatment options, and aims to improve their quality of life through advanced scientific research and clinical trials. The business model revolves around the discovery, development, and commercialization of novel therapeutic solutions. Cerecor generates revenue through public offerings, strategic partnerships, and the eventual commercialization of its drug candidates. The company is listed on the Nasdaq under the ticker symbol CERC and actively engages in investor relations to secure funding for its ambitious projects.

Keywords: biopharmaceutical, rare diseases, pediatric, orphan diseases, innovative therapies, clinical trials, Nasdaq, healthcare, biotechnology, drug development.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Avalo Therapeutics

Edit
Zylera Pharmaceuticals
ACQUISITION by Avalo Therapeutics Nov 2017
AlmataBio
ACQUISITION by Avalo Therapeutics Mar 2024